Apatinib as post second-line therapy in EGFR wild-type and ALK-negative advanced lung adenocarcinoma

Figures & data

Figure 1 Patient I: Computed tomography shows the mass in the right lung with left lung metastasis and pleural effusion (A) before apatinib treatment and (B) after apatinib treatment was given for 2 weeks.

Table 1 Baseline characteristics of patients

Characteristics	Case 1	Case 2	Case 3
Age (years)	70	42	66
Sex	Female	Female	Male
Smoking	No	No	Light smoker
Pathologic type	Adenocarcinoma	Adenocarcinoma	Adenocarcinoma
Gene type
EGFR	Wild-type	Wild-type	Wild-type
ALK	Negative	Negative	Negative
Stage	IV (cT4N2M1b)	IV (cT4N1M1a)	IV (cT4N1M1a)
Therapy (response)
First line	Pemetrexed/cisplatin (PR)	Pemetrexed/cisplatin (PR)	Pemetrexed/cisplatin (SD)
Second line	Docetaxel (PD)	Docetaxel/carboplatin (SD)	Docetaxel/carboplatin (PD)
Third line	Apatinib (PR)	Gemcitabine/nedaplatin (PD)	Apatinib (PR)
Fourth line		Apatinib (PR)
CEA (µg/mL)
Pre-apatinib	85	28	56
Post-apatinib	35	16	20
PFS (months)	2.8	5.8	6
Adverse events
Hypertension	Grade 2	Grade 3	Grade 3
Hand–foot		Grade 2
syndrome
Proteinuria	Grade 1

Abbreviations: ALK, anaplastic lymphoma kinase; CEA, carcinoembryonic antigen; EGFR, epidermal growth factor receptor; PD, progressive disease; PFS, progression-free survival; PR, partial response; SD, stable disease.

Figure 2 Patient II: Computed tomography shows the mass in the right lung (A) before apatinib treatment and (B) after apatinib treatment was given for 1 month.

Figure 3 Patient III: Computed tomography shows the mass in the right lung (A) before apatinib treatment and (B) after apatinib treatment was given for 3 weeks.